WHO’s Biologic Naming Plan Draws Questions Of Retroactive Naming, Use

Key biosimilar and biologic developers came down on different sides as to how a World Health Organization plan for biological qualifiers should apply in practice, with Hospira pressing for its use only for pharmacogivilance, not for prescribing, and originator companies pushing to have BQs appear wherever International Nonproprietary Names are used, including prescribing. The use of BQs and other key outstanding issues, such as how biologics could be retroactively named, are likely to be discussed at the WHO’s next naming...

Subscriber Login

If you are a InsideHealthPolicy.com subscriber, or you have an active trial subscription, please login here:

Enter your InsideHealthPolicy.com username.
Enter the password that accompanies your username.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.